Sorrento Receives EUA Approval and Import License From Mexico Authority COFEPRIS For COVI-STIX™ (COVID-19 Virus Rapid Antigen Detection Test) and Plans Product Launch With Initial Shipments in July
June 24, 2021 13:13 ET
|
Sorrento Therapeutics, Inc.
Sorrento received official EUA registration and product import license: COFEPRIS EUA registration number “OFICIO: CAS/10720/2021”.Sorrento is establishing its “Sorrento Mexico Ltd” subsidiary to...
Sorrento Enters Into Multi-Year Cooperative Research and Development Agreement With the U.S. Naval Medical Research Unit – No. 3 (NAMRU-3) For Pandemic Preparedness Combating COVID-19
June 22, 2021 13:46 ET
|
Sorrento Therapeutics, Inc.
Broad multi-year agreement between Sorrento Therapeutics and U.S. Naval Medical Research Unit – No. 3 (NAMRU-3) headquartered in Sigonella, Italy with Laboratory Detachments in Cairo, Egypt, Camp...
Sorrento Announces Phase 2 Abivertinib Clinical Studies Have Completed Patient Enrollment in USA and Brazil with Top-Line Clinical Data Expected End of 3Q21
June 22, 2021 09:00 ET
|
Sorrento Therapeutics, Inc.
Phase 2 US clinical trial of Abivertinib randomized last patient (#96) on 4/07/2021.Phase 2 Brazilian clinical trial of Abivertinib randomized last patient (#400) on 06/20/2021.Studies are...
Sorrento Receives Authorization From the UK Regulatory Agency to Conduct a Phase 2 Clinical Trial for COVI-DROPS in an Outpatient Setting
June 11, 2021 16:11 ET
|
Sorrento Therapeutics, Inc.
Large Phase 2 efficacy trial cleared to start in the United Kingdom in newly diagnosed SARS-CoV-2 infected patients.COVI-DROPS is administered by intranasal drops and the antibody is active against...
Sorrento Announces Clinical Research Agreement With Mayo Clinic and FDA Clearance for the First Phase 1b Pilot Study Using Sofusa Lymphatic Drug Delivery Technology to Deliver Ipilimumab in Patients With Melanoma
June 11, 2021 09:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, June 11, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced a research collaboration agreement with Mayo Clinic to conduct human clinical...
Sorrento Announces Positive Results From Its License Partner, Kelun, on a Phase I Study of Safety and Pharmacokinetics of A166, a Novel HER2 ADC for Advanced HER2 Positive Breast Cancers
June 04, 2021 15:13 ET
|
Sorrento Therapeutics, Inc.
A166 (ASCO Abstract #1024) is a third generation antibody drug conjugate (ADC) against HER2-positive breast cancer with Levena’s proprietary tubulin inhibitor Duo-5 toxin, cleavable linker and...
Sorrento and Researchers at Karolinska Institutet Have Signed a Research Collaboration Agreement on iPSC-Derived Dimeric Antigen Receptor-Modified Natural Killer (DAR-NK) Cells With The Vision to Bring “Off-The-Shelf" NK Cell-Based Cancer Treatments Rapidly to Patients
June 04, 2021 13:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO and STOCKHOLM, Sweden, June 04, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the Company has entered into an additional...
Sorrento Completes Acquisition of ACEA Therapeutics, Creating a Major Oncology Franchise
June 02, 2021 09:00 ET
|
Sorrento Therapeutics, Inc.
AMONG MULTIPLE CLINICAL- AND PRECLINICAL-STAGE NCE (NEW CHEMICAL ENTITY) COMPOUNDS ACQUIRED, ABIVERTINIB IS AN ANCHORING LATE-STAGE DRUG PRODUCT WITH POSITIVE CLINICAL TRIAL RESULTS IN BOTH NON-SMALL...
Sorrento Announces Addition of COVI-STIX™ (Covid-19 Virus Rapid Antigen Detection Test) to the Official Mexican Government List of Emergency Use Approved Point of Care Rapid Antigen Tests
June 02, 2021 07:00 ET
|
Sorrento Therapeutics, Inc.
COVI-STIX has been added to the official government list of point of care rapid antigen tests useful for the detection of SARS-CoV-2 in Mexico...
Agência Nacional de Vigilância Sanitária (ANVISA) autoriza Fase 2 Sorrento do Ensaio Clínico Principal de COVI-MSC™ em Pacientes Hospitalizados com Síndrome do Distúrbio Respiratório Agudo com COVID-19
May 20, 2021 15:38 ET
|
Sorrento Therapeutics, Inc.
A Fase 2 do Ensaio Clínico Principal de COVI-MSC agora está autorizado a prosseguir.O estudo irá comparar a terapia usando células-tronco mesenquimais no placebo (e tratamento padrão) em 100 pacientes...